1020 ET - Tuesday's 27% selloff in Sarepta Therapeutics after the death of a patient who received its Elevidys gene therapy makes for a compelling buying opportunity, according to Mizuho. In a note, Mizuho's Uy Ear says Sarepta's current stock price captures little value for Elevidys, as the value of Sarepta's exon-skipping for Duchenne Muscular Dystrophy and limb-girdle muscular dystrophy businesses add up to about $70 a share. Mizuho, with an outperform rating and $190 price target on Sarepta, says Sarepta management is standing by its 2025 guidance, and the analysts still see the Elevidys benefit/risk profile as positive. Sarepta up 6.3% to $78.09. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
March 19, 2025 10:20 ET (14:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。